Comparative Pharmacology
Head-to-head clinical analysis: PAMELOR versus PRAMINE.
Head-to-head clinical analysis: PAMELOR versus PRAMINE.
PAMELOR vs PRAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nortriptyline, the active ingredient, is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at the presynaptic neuronal membrane, increasing their availability in the synaptic cleft.
Tricyclic antidepressant; inhibits reuptake of norepinephrine and serotonin at presynaptic neuronal membrane, increasing their concentration in the synaptic cleft.
25-150 mg orally per day, typically as a single daily dose at bedtime or in divided doses; start at 25 mg 1-3 times daily and titrate gradually. Maximum 150 mg/day.
Imipramine (PRAMINE) 75-150 mg orally once daily at bedtime, titrated from 25-50 mg, max 300 mg/day.
None Documented
None Documented
Clinical Note
moderateImipramine + Torasemide
"The risk or severity of adverse effects can be increased when Imipramine is combined with Torasemide."
Clinical Note
moderateClomipramine + Torasemide
"The risk or severity of adverse effects can be increased when Clomipramine is combined with Torasemide."
Clinical Note
moderateImipramine + Etacrynic acid
"The risk or severity of adverse effects can be increased when Imipramine is combined with Etacrynic acid."
Clinical Note
moderateClomipramine + Etacrynic acid
Mean terminal elimination half-life is 18-24 hours (range 13-40 hours) in adults; prolonged in elderly and hepatic impairment (up to 60 hours). Steady-state achieved in 4-5 days.
10-12 hours (terminal elimination half-life; may be prolonged in elderly and hepatic impairment)
Primarily renal (approximately 70% as metabolites, 40-50% as glucuronide conjugates, 20-30% as free or conjugated nortriptyline; <5% unchanged), with 20-30% biliary/fecal elimination.
Renal: 70% (as metabolites); Fecal: 30% (as metabolites and unchanged drug)
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant
"The risk or severity of adverse effects can be increased when Clomipramine is combined with Etacrynic acid."